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quinoline-3-carboxamide anti-angiogenic agent, 
modulates the expression of thrombospondin-1 in 
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Abstract
Background: The orally active quinoline-3-carboxamide tasquinimod [ABR-215050; CAS number 254964-60-8), which 
currently is in a phase II-clinical trial in patients against metastatic prostate cancer, exhibits anti-tumor activity via 
inhibition of tumor angiogenesis in human and rodent tumors. To further explore the mode of action of tasquinimod, 
in vitro and in vivo experiments with gene microarray analysis were performed using LNCaP prostate tumor cells. The 
array data were validated by real-time semiquantitative reversed transcriptase polymerase chain reaction (sqRT-PCR) 
and protein expression techniques.
Results: One of the most significant differentially expressed genes both in vitro and in vivo after exposure to 
tasquinimod, was thrombospondin-1 (TSP1). The up-regulation of TSP1 mRNA in LNCaP tumor cells both in vitro and in 
vivo correlated with an increased expression and extra cellular secretion of TSP1 protein. When nude mice bearing 
CWR-22RH human prostate tumors were treated with oral tasquinimod, there was a profound growth inhibition, 
associated with an up-regulation of TSP1 and a down- regulation of HIF-1 alpha protein, androgen receptor protein 
(AR) and glucose transporter-1 protein within the tumor tissue. Changes in TSP1 expression were paralleled by an anti-
angiogenic response, as documented by decreased or unchanged tumor tissue levels of VEGF (a HIF-1 alpha down 
stream target) in the tumors from tasquinimod treated mice.
Conclusions: We conclude that tasquinimod-induced up-regulation of TSP1 is part of a mechanism involving down-
regulation of HIF1α and VEGF, which in turn leads to reduced angiogenesis via inhibition of the "angiogenic switch", 
that could explain tasquinimods therapeutic potential.
Background
During the last decades, development of new cancer
treatments that are capable of inhibiting tumor growth by
inhibition of the blood supply has received great atten-
tion [1,2]. The quinoline compound tasquinimod [ABR-
215050; CAS number 254964-60-8; 4-hydroxy-5-meth-
oxy-N,1-dimethyl-2-oxo-N-[(4-trifluoromethyl) phenyl]-
1,2-dihydroquinoline-3-carboxamide] has emerged as a
candidate [3], by virtue of its pharmacological profile
with anti-angiogenic and anti-tumor potency in experi-
mental human prostate cancer models [4,5]. Thrombos-
pondin-1 (TSP1) is a 450 kDa glycoprotein initially found
in platelets, but also synthesized and secreted by many
normal and transformed cells. TSP1 has been shown to
be a potent natural inhibitor of tumor progression and
metastases via inhibition of angiogenesis and migration
or by activation of TGFβ (for review see [6-8]). Several
mechanisms have been proposed for the anti-angiogenic
properties of TSP1. For example, its type 1 repeat pep-
tides (TSRs) [9] bind to and induce CD36-receptor sig-
naling in endothelial cells and consequently lead to
induction of apoptosis in endothelial tissue [10,11].
TSP1-induced signaling via CD47 and CD36 receptors
expressed in endothelial cells also results in suppression
of NO-dependent vascular pathways [12,13], and TSP1
acts as an apoptosis independent inhibitor of cell cycle
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progression [8]. Also, TSP1 inhibits neovascularization
by interfering with FGF- and/or VEGF-induced angio-
genesis via binding to, and blockage of, its receptors on
the endothelial cell [14]. Furthermore, TSP1 negatively
regulates the tissue levels of pro-angiogenic inducers (i.e.
VEGF and FGF) and thereby shunts the "angiogenic
switch" into an anti-angiogenic state [7,15]. Tissue level
expressions of TSP1 are repressed by androgens in nor-
mal and cancer prostate tissue [16,17], and are down-reg-
ulated by several oncogenes including c-fos, c-jun, and
Ras [18]. However, tumor suppressors such as PTEN, p53
and angiotensin II, but also PI3-kinase, β1C integrin, his-
tone deacetylase (HDAC) inhibitors, and anti-cancer
agents like dexrazoxane, up-regulate TSP1 levels [18-23].
Moreover, TSP1 modulates the expression of interleukin
IL-6 and IL-10 by human monocytes [24], which both
have impact on tumor vascularization. Lastly, TSP1
inhibits inflammation [25] and promotes the recruitment
of M1-polarized macrophages (TAM:s) [26] that express
high levels of iNOS (inducible NO synthetase) [27].
Many different approaches have been used to increase
the systemic levels of TSP1 in order to inhibit angiogene-
sis and counteract cancer growth. Among these
approaches are metronomic therapy (i.e. continuous low
dose chemotherapy) [28], and systemic delivery of
recombinant proteins [29] or synthetic peptides [13,30]
with TSR sequences the most successful. In the present
study we investigated the molecular changes that underlie
the anti-tumor effects of tasquinimod in human prostate
c a n c e r  c e l l s  ( L N C a P ) .  W e  o b s e r v e d  e l e v a t e d  l e v e l s  o f
TSP1 mRNA and protein expression in both cell cultures
and tumor tissue after exposure to tasquinimod. Thus, we
were able to identify a possible mechanism for the anti-
tumor effect of tasquinimod, involving up-regulation of
TSP1 and inhibition of the "angiogenic switch".
Results
Tasquinimods effects on gene expression in LNCaP cells 
analyzed with DNA microarray
Tasquinimod has been documented to have a robust and
consistent anti-angiogenic activity in vitro at doses
between 10-50 μM and in vivo at 1-10 mg/kg/day result-
ing in a potent anti-tumor effect in rodent and human
prostate cancer xenografts tested in the same dose ranges
[4,5]. Generated microarray data based on four separate
biological replicates showed a drug-induced effect of 50
μM tasquinimod on gene expression in LNCaP cells
when cultured in vitro for 24 h. Up- and down-regulation
(FDR < 0.1; z-test) was noted for 107 genes (Additional
file 1, Table S1). An in vivo experiment with LNCaP
t u m o r s  i n o c u l a t e d  ( s . c . )  i n t o  n u d e  m i c e  w a s  a l s o  p e r -
formed. Tumor bearing mice (n = 2) were exposed to
ABR-215050 at 10 mg/kg for 24 h at day 14 and day 21
after inoculation before the tumors were excised. There
was a similar gene expression pattern between the two 24
h time points, and for this reason day 14 and day 21 data
were pooled (n ≤ 4, Additional file 2, T able S2). T able 1
lists a selected number of significantly up- or down-regu-
lated genes after 24 h exposure to ABR-215050 (in vivo
and/or in vitro). The presented genes were derived from
significant clusters generated by a functional cluster anal-
ysis performed in the "DAVID and EASE" data base
[31,32]. Briefly, the cluster analysis and pathway mapping
revealed that many differentially expressed genes were
involved in angiogenesis, cell cycle and apoptosis, migra-
tion, metabolism, signalling, DNA damage and oxidative
stress (Table 1). Five of these genes, thrombospondin-1
(THBS1; TSP1), chemokine receptor CXCR4, cyto-
chrome P450 1A1 (CYP1A1), receptor for advanced gly-
cosylation endproduct (AGER; RAGE), and growth
differentiation factor 15 (GDF15), were chosen for fur-
ther validation using real time semi-quantitative RT-PCR.
The expression data achieved by RT-PCR (Fig. 1B) were
consistent with the microarray analysis data with a signif-
icant up-regulation of THBS1,  GDF15  and  CYP1A1
whereas CXCR4 and AGER1 did not change expression
significantly (Fig. 1B and Table 1). Thus, the data
achieved by microarray analysis after exposure to tas-
quinimod demonstrated a good agreement with semi-
qRT-PCR as an independent validation method.
TSP1 mRNA and protein induction by tasquinimod in vitro 
cell cultures of tumor cells
Among the most significant gene differentially expressed
both in cell cultures and in tumor tissue after exposure to
tasquinimod, was TSP1 (THBS1; indicated by arrow in
Fig. 1A). The up-regulation of TSP1 mRNA levels in
LNCaP cells after exposure to tasquinimod was further
investigated by semi-qRT-PCR. TSP1 mRNA induction
was dependent both on dose and time. At 10 μM tasquin-
imod the TSP1 mRNA expression was elevated at 6 h and
peaked after 72 h (Fig. 2A). Moreover, after 72 h exposure
the TSP1 mRNA levels was already elevated at a dose of 1
μM tasquinimod (Fig 2B), indicating that tasquinimod-
induced changes in TSP1 mRNA expression occurred in a
dose range that has an documented anti-angiogenic and
anti-tumor effect in in vivo xenograft models [5]. At
higher dose levels (i.e. 50-100 μM) the mRNA levels
declined at 72 h, indicating additional drug effects at
these concentrations. The up-regulation of TSP1 mRNA
in LNCaP cells by tasquinimod was manifested by an
increased expression of TSP1 protein, as shown by west-
ern blot analysis of cell lysates prepared from cells cul-
tured for 24 h and 72 h (Fig. 3A). Accompanied by
increased intracellular TSP1 protein levels was also a sta-
tistically significant (p < 0.05) accumulation of extracellu-
lar TSP1 in the cell culture medium detected (Fig. 3A (ii)).
The extracellular secretion of TSP1 was time dependentOlsson et al. Molecular Cancer 2010, 9:107
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Table 1: Selected genes differentially expressed in LNCaP prostate tumor cells after exposure to tasquinimod for 24 h.
Functional groups*
Gene name
Accession #† Gene‡ Locus In vitro In vivo
Angiogenesis/hypoxia
CD36 antigen (TSP1 receptor) NM_001001547 CD36 948 +
Vascular endothelial growth factor NM_001025366 VEGF 7442 -
Thrombospondin 1 (THBS1, TSP1) NM_003246 THBS1 7057 ++ * *
Endothelial PAS domain protein 1 NM_001430 EPAS1 2034 +
Neuropilin 2 NM_003872 NRP2 8828 +
Stabilin1 NM_015136 STAB1 23166 +
Angiopoietin 2 NM_001147 ANGPT2 285 --
Cadherin 13 NM_001257 CDH13 1012 +
Hypoxia-inducible protein 2 NM_013332 HIG2 29932 -
Cell cycle/differentiation/senescence/
apoptosis
Cyclin-depenent inhibitor kinase 1C NM_000076 CDKN1C 1028 -
Adrenomedullin NM_001124 ADM 133 -
Fibroblast growth factor NM_033136 FGF1 2246 +
Advanced Glycosylation Endproduct Recept NM_001136 AGER 177 -
Leukocyte specific transcript protein 1 NM_007161 LST1 7941 +
Forkhead box protein N4. NM_213596 FOXN4 121643 +
Jun D proto-oncogene; AP-1 complex NM_005354 JUND 3727 -
Invasion/migration/adhesion/metastasis
Lysyloxidase preprotein NM_002317 LOX 4015 --
Secreted phosphoprotein NM_00582 SPP1 6996 -
Chemokine (C-X-C motif) receptor 4 NM_003467 CXCR4 7852 -
Spleen tyrosine kinase NM_003177 SYK 6850 +
Vimentin NM_003380 VIM 7431 +
CD44 antigen isoform a NM_000610 CD44 960 +
CD74 antigen NM_004355 CD74 972 +
Insulin-like growth factor binding prot 3 NM_000598 IGFBP3 3486 -
S100 calcium-binding protein A6 NM_014624 S100A6 6277 +
S100 calcium binding protein P NM_005980 S100P 6286 +
P8 protein (candidate of metastasis 1) NM_012385 NUPR1 26471 -
Matrix metalloproteinase 14 NM_004995 MMP14 4323 +
Latent transforming GFB-binding prot NM_032035 LTBP2 4053 +
Insulin-like growth factor binding prot 7 NM_001553 IGFBP7 3490 +
Stress response/metabolism/DNA repair
cytochrome P450, family 1, subfamily A NM_000499 CYP1A1 1543 ++
cytochrome P450, family 1, subfamily A NM_000761 CYP1A2 1544 +
growth differentiation factor 15 (NAG1) NM_004864 GDF15 9518 +
DNA-damage-ind. transcript 3 (GADD153) NM_004083 DDIT3 1649 +-
TCDD-inducible poly(ADP-ribose) polymerase NM_015508 TIPARP 25976 ++
Tumor protein p53 inducible nulear prot 2 NM_021202 TP53INP2 58476 +Olsson et al. Molecular Cancer 2010, 9:107
http://www.molecular-cancer.com/content/9/1/107
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and could clearly be detected after 24 h exposure to tas-
quinimod at 10 μM (Fig. 3B). Also, TSP1 mRNA levels
were induced by tasquinimod at 10 μM in the hormone
insensitive cell line LNCaP19 but not in DU145 cells (Fig.
3C). The elevated mRNA levels was reflected in a minor
increase of intracellular TSP1 protein levels in LNCaP19
cells expressed as a major band of intact protein around
150 kD (Fig. 3D). Taken together, the data obtained from
in vitro exposure of human prostate cancer cells to tas-
quinimod demonstrate a drug effect resulting in increases
of both TSP1 mRNA and protein expression.
Up-regulation of TSP1 mRNA and protein levels in vivo in 
tumor tissue
Nude mice carrying subcutaneous LNCaP tumors were
treated with tasquinimod for 3 weeks. Exposure to tas-
quinimod at 1 mg/kg/day and 10 mg/kg/day started on
day 7 after inoculation. There was a statistically signifi-
cant dose dependent reduction in tumor weight both at 1
mg/kg/day and 10 mg/kg/day compared to the untreated
control group 28 days after inoculation (p < 0.001,
ANOVA; Fig. 4A), illustrating the anti-tumor effect of
tasquinimod. The tumor tissue levels of VEGF protein
were not increased (Fig. 4B), whereas drug-induced
changes in the tumor TSP1 mRNA expression at 10 mg/
kg/day (p < 0.05; Fig. 4C (i)) and in protein levels at 1 and
10 mg/kg/day were significantly higher after 3 weeks
exposure to tasquinimod (p < 0.001, ANOVA; Fig. 4D).
The absence of mRNA induction at 1 mg/kg/day, how-
ever, may reflect the difficulty to detect smaller changes
in mRNA levels after 3 weeks of continuous exposure at a
relatively low dose and that mRNA expression and pro-
tein expression not always appear at the same levels in the
tissue.
As a control, because the TSP1 antibody (rabbit poly-
clonal Ab8) cross-reacts with TSP1 of mouse origin,
mRNA levels of mouse TSP1 was also measured, to
assure that host derived TSP1 was not the source of
increased TSP1 production in the treated tumors via
infiltrating cells and blood (Fig. 4C(ii)). Immunofloures-
ence microscopy clearly showed TSP1 protein expression
in LNCaP tumors (Fig. 4E). The most intense labeling was
found in regions between zones of tumor growth and
peripheral growth regions close to the tumor capsule
("the viable rim"). TSP1 was mainly localized in the extra
cellular matrix in relation to blood vessels (Fig. 4E, inset).
Thus, the elevated mRNA and protein levels of tumor
derived TSP1 in vivo paralleled the observed changes in
TSP1 mRNA- and protein expression in vitro.
Tasquinimod blocks the angiogenic switch in CWR-22RH 
tumors
The term "angiogenic switch" denotes that in order for
cancer to continuously grow, tumors must down-regulate
natural angiogenesis inhibitors like TSP1, while coordi-
nately up-regulating angiogenesis stimulators like VEGF
[33]. When nude mice bearing CWR-22RH human pros-
tate cancers were treated with oral tasquinimod, there
was a profound growth inhibition (Fig. 5A; p < 0.01).
Associated with this growth inhibition was a decreased
tumor tissue level of VEGF (i.e. a down stream target of
HIF1α) (Fig. 5B; p < 0.05). Likewise there was a significant
up-regulation of TSP1 protein coupled with a down-regu-
lation of HIF1α protein, androgen receptor protein (AR),
and glucose transporter-1 protein (i.e. down stream tar-
get of HIF1α) within tasquinimod treated tumor tissues
excised and prepared on day 28 (Fig. 5C; p < 0.05). Com-
bined, these data clearly document that tasquinimod has
inhibited the "angiogenic switch" within LNCaP and
CWR-2RH xenografts.
Discussion
In this report we have identified TSP1 as an important
player in order to understand and explain the mechanism
of the anti-angiogenic, and consequently the anti-tumor
effect of tasquinimod treatment of prostate cancer. By
using DNA microarray technique to monitor changes in
mRNA expression after tasquinimod exposure, in vitro to
cultured human LNCaP cells or in vivo to LNCaP tumors
grown in nude mice, we were able to identify TSP1 as one
potential candidate, among many other differentially
expressed genes, for mediating the tasquinimod-induced
anti-tumor activity. The increased expression of TSP1
mRNA was further validated by qRT-PCR and on protein
Inflammatory response
Myeloperoxidase NM_000250 MPO 4353 -
Interleukin 8 receptor beta NM_001557 IL8RB 3579 -
Interleukin 12 alpha chain NM_000882 IL12A 3592 -
Serpin peptidase inhibitor 1 NM_001085 SERPINA3 12 -
* Functional classification by gene annotation enrichment analysis, gene clustering analysis and pathway mapping based on Gene Ontology 
data in DAVID Bioinformation database, † Genebank accession number.
‡Presented genes were significantly up (+) or down (-) regulated (FDR < 10%) in ≥3 out of 4 biol replicates.
** Expressed in 2 out of 4 replicates
Table 1: Selected genes differentially expressed in LNCaP prostate tumor cells after exposure to tasquinimod for 24 h. Olsson et al. Molecular Cancer 2010, 9:107
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Figure 1 Tasquinimod effects on gene expression in LNCaP cells analyzed with DNA microarray. Altered gene expression induced by tasquin-
imod in LNCaP cell cultures. (A) Data plot of observed M ((M) = log2(Int1/Int2)) versus A (average intensity) from in vitro microarray experiment aver-
aged over biological replicates (n = 4). THBS1 (arrow), GDF15 and CYP1A1 were significant outliers in all arrays analyzed (FDR < 10%; Table 1). (B) 
Validation of microarray data with semi-qRT-PCR confirmed the up-regulation of THBS, GDF14 and CYP1A1 (red bars; Δcp of 2.32 equals to a 5-fold 
change in mRNA expression). Expressed data represents the mean ± SD of at least two independent experiments. (*) p ≤ 0.05 and (**) p ≤ 0.01 com-
pared with untreated control (Student's t-test).
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level with western blot and histochemical analysis. Gen-
erally, there was a similar gene induction pattern on
microarrays from tumor RNA after in vivo exposure. The
good agreement between gene induction data achieved
by microarray technique and RT-PCR was taken as evi-
dence that the gene induction pattern observed on the
microarrays were reliable and reflected an accurate pic-
ture of tasquinimod-induced gene expression. Despite
the limited numbers of doses and time points, we were
able to identify several interesting groups of functional
clusters which may be involved in tasquinimods anti-
tumor activity, such as angiogenesis, cell cycle regulation
and migration (Table 1).
The nature of tasquinimod-induced increases in
mRNA expression measured in tumor tissue after in vivo
exposure is probably both of a direct and an indirect
character. For example, TSP1, CYP1A1, and GDF15
mRNA induction are most likely reflecting a direct induc-
ing effect on the tumor cells, because elevated mRNA lev-
els were also achieved in vitro in cell cultures where no
other cell types were present. On the contrary, genes
involved in angiogenesis, cell cycle events or cell prolifer-
ation may be of an indirect or secondary nature and have
a slower kinetic profile. With this in mind, up-regulation
of for example the pro-angiogenic FGF1 in the LNCaP
tumors were considered of minor importance compared
to VEGF since we were not able to measure the FGF lev-
els (by ELISA) in tumors or in cell culture medium from
untreated cells or cells treated with tasquinimod (data not
shown). TSP1 up-regulation in LNCaP cells involves dif-
ferent pathways including genes such as the PI3K, Akt,
PTEN, IGFBP3, p21 (Waf-1) and p53 [19,22], and indeed
some of these genes changed expression by tasquinimod
exposure in our microarray experiments (Table 1).
In contrast, androgens and the androgen receptor (AR),
which is expressed and functional in both LNCaP and
CWR-22RH cells, have been reported to suppress TSP1
expression in tumor cells [34]. Colombel et al. showed
that androgen ablation resulted in up-regulation of TSP1
which initially produced an anti-angiogenic response
[17]. This therapeutic response was only temporary how-
ever, since the cancer cells in the resulting hypoxic envi-
ronment eventually up-regulated the production of
VEGF and thus became completely resistant to the
enhanced TSP1 levels. In contrast to this rebound situa-
tion following androgen ablation, tasquinimod prevented
such up-regulation of VEGF (Figs. 4B and 5B) and thus
does not allow the tumor to overcome TSP1 anti-angio-
genic effects. This may provide a mechanism that
explains why tasquinimod treatment is synergistic when
combined with androgen ablation [4]. Our data indicated
a gradual difference in TSP1 induction and expression
levels between androgen sensitive and refractive tumor
cells. There was an evident induction of TSP1 expression
at both mRNA and protein levels in the androgen sensi-
tive tumor cells LNCaP and CWR-22RH, whereas there
was less induction in LNCaP19, and no measurable
induction above constitutive protein levels in the hor-
mone refractive DU145 which lack the androgen receptor
completely. Thus, tasquinimod exposure resulting in
induction of TSP1 expression may involve effects on the
AR and maybe also p53 activity, since cross-talk between
these genes has been reported [35]. Besides transcrip-
tional regulation, the anti-angiogenic activity by TSP1
requires proteolysis to liberate soluble anti-angiogenic N-
terminal deletion fragments from extra-cellular matrix
bound TSP1 and that tumor associated macrophages
(TAM's) secrete ADAMTS1, which can perform this
TSP1 fragmentation [36]. Once liberated, these soluble
TSP1 N-terminal deletion fragments bind VEGF and
FGF's in a way that prevents them from stimulating
endothelial cells [37,38]. Such a process may require
Figure 2 TSP1 mRNA induction by tasquinimod in in vitro tumor 
cell cultures. Tasquinimod-induced mRNA expression in LNCaP cells 
measured by real time semi-quantitative RT-PCR. (A) Time study after 
in vitro exposure with 10 μM tasquinimod, and (B) dose response with 
tasquinimod treatment between 0.1-100 μM for 72 h (p = 0.0128, ANO-
VA). Data expressed represents the mean ± SD of at least two indepen-
dent experiments. (*) p ≤ 0.05 and (**) p ≤ 0.01 compared with 
untreated control (Bonferroni's multiple comparison test).
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Figure 3 TSP1 expression by LNCaP cells after tasquinimod exposure in in vitro cell cultures. (A) Up-regulation of the TSP1 protein levels by 
tasquinimod (50 μM) in LNCaP cells was measured by western blot analysis (left panel (i)). Protein bands represent intact TSP1 at ~160 kD (monoclonal 
Ab11). TSP1 secreted into cell culture medium was measured with ELISA after 72 h (right panel (ii)). The culture medium levels of TSP1 were 50.8 ± 1.5 
ng/ml for untreated cells and 80.6 ± 10.2 ng/ml for exposed cells, respectively (n = 3; p ≤ 0.05, ANOVA). (B) TSP1 secretion into cell culture medium 
after exposure of LNCaP cells to 10 μM tasquinimod (+) (p ≤ 0.01, ANOVA). TSP1 levels in untreated (-) cell culture medium were 22, 36.6 and 51.6 ng/
ml after 6, 24 and 72 h incubation, respectively, and 6 ng/ml in the R10 medium. (C) Up-regulation of TSP1 mRNA levels occurred in the hormone 
independent prostate cancer cell line LNCaP19 but not in DU145, (-) untreated control and (+) 10 μM tasquinimod (p ≤ 0.0001; ANOVA). Presented 
data represent the mean ± SD of at least two independent experiments. (*) p ≤ 0.05 and (**) p ≤ 0.01 compared with untreated control (Bonferroni's 
multiple comparison test). (D) TSP1 protein levels measured by western blot analysis of prostate cancer cell lysates, (-) untreated control and (+) 10 
μM tasquinimod for 72 h. PL indicates lysate prepared from human platelets and rTSP1 is recombinant TSP1.
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Figure 4 Anti-tumor effect and up-regulation of tumor associated human TSP1 mRNA levels in tasquinimod treated LNCaP tumors. Anti-
tumor effect in nude mice carrying subcutaneous LNCaP tumors treated with tasquinimod (10 mg/kg/day) for three weeks. The treatment started 7 
days after inoculation, and expressed data represent the mean tumor weight ± SD (n = 5; p = 0.0076, ANOVA). (B) VEGF levels were measured in pro-
cessed tumor tissue by ELISA. (C) Up-regulation, monitored with real-time qRT-PCR, of tumor associated human TSP1 mRNA levels ((i); p = 0.0216, 
ANOVA) in LNCaP tumors. To distinguish between mRNA from human tumor cells and infiltrating mouse cells, TSP1 mRNA was analyzed using primers 
specific for human (i) or mouse (ii) sequences with the same probe set (Table 2). (D) Elevated protein levels of tumor-produced human TSP1 (rabbit 
polyclonal Ab8). Each lane represents a tumor sample from an individual animal. Calculated ratios between the major band of intact TSP1 (approxi-
mately at 150-160 kD) and actin in each lane show a significant (p = 0.0004, ANOVA) up-regulation of TSP1 tumor levels in exposed animals ((+); n = 
4) compared to untreated controls (-). (*) p ≤ 0.05 and (**) p ≤ 0.01 (Bonferroni's multiple comparison test). (E) TSP1 expression (green) analyzed by 
IHC microscopy in LNCaP tumor tissue exposed in vivo to tasquinimod at 10 mg/kg/day (bar = 50 μm). TSP1 was mainly localized in the extra cellular 
matrix (inset). Blue shows DAPI staining.
Control 1mg/kg 10mg/kg
0
25
50
75
100
n
g
 
V
E
G
F
/
 
g
 
t
i
s
s
u
e
Control 1 mg/kg 10 mg/kg
0.0
0.2
0.4
0.6
0.8
1.0
*
**
R
a
t
i
o
 
T
S
P
1
/
a
c
t
i
n
Actin
TSP1
D.
C.
A. B.
   Control          1mg/kg          10mg/kg rTSP1
Control 1 mg/kg 10 mg/kg
0
50
100
150
200
250
 **
*
T
u
m
o
r
 
w
e
i
g
h
t
 
(
m
g
)
Control 1 mg/kg 10 mg/kg
0
1
2
3
4
*
(i)  human TSP1
F
o
l
d
 
c
h
a
n
g
e
Control 1 mg/kg 10 mg/kg
0
1
2
3
4 (ii)  mouse TSP1
F
o
l
d
 
c
h
a
n
g
e
E.
TSP1 (green) / DAPI (blue)
+   +   +   +  -    -    -   - +   +   +   +
150kD
37kDOlsson et al. Molecular Cancer 2010, 9:107
http://www.molecular-cancer.com/content/9/1/107
Page 9 of 14
TAMs to attain tasquinimod's optimal activity in vivo.
R e c e n t l y  i t  w a s  r e p o r t e d  t h a t  T S P 1  m o d u l a t e s  V E G F
activity at the VEGF receptor level via its TSR interaction
and co-clustering with CD36 and β1 integrins [39]. The
documented anti-angiogenic and anti-tumor of up-regu-
lated TSP1 in prostate cancers does however not always
be the case for other types of cancers [40], indicating a
dual effect of TSP1 on angiogenesis and tumor progres-
sion (reviewed by [41]).
Figure 5 Tasquinimod blocks the angiogenic switch in CWR-22RH tumors. Inhibition of the "angiogenic switch" was illustrated in treated CWR-
22RH tumors. (A) Tumor growth reduction of CWR-22RH human prostate tumors inoculated into nude mice after oral treatment with tasquinimod at 
10 mg/kg/day, data points represent the average ± SD, (n = 5, (**) p = 0.002; Mann-Whitney U). (B) Reduced tumor levels of VEGF, a downstream HIF1α 
target gene. Bars represent the mean ± SD, n = 5 and (*) p < 0.05. (C) The up-regulation of TSP1 (mouse monoclonal Ab11) in tumor tissue excised 
and prepared as whole cell lysates (10,000 g supernatant) was accompanied with a down-regulation of the androgen receptor (AR), HIF1α, and Glut-
1. (i) Each lane represents a tumor sample from an individual animal (#11 to #15 controls and #21 to #25 exposed to tasquinimod). Molecular weight 
markers for each blot are indicated. (ii) Calculated ratios between the major protein bands and actin for each lane show a statistical significant differ-
ence between exposed animals (#T21 - #T25) compared to untreated controls (#T11-#T15). (*) p ≤ 0.05, (**) p ≤ 0.01 and (***) p ≤ 0.001 (Bonferroni's 
multiple comparison test).
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The mode of action behind of the quinoline com-
pounds anti-tumor properties has not been fully resolved,
but several studies have shown that this group of com-
pounds effect tumor angiogenesis [4,5], macrophage
infiltration [42], cytokine production [43], and autoim-
mune/inflammatory disease [44]. Hence, the immuno-
modularly properties of the quinolines indicate existence
of an immunological component as a key player in quino-
line compounds mode of action resulting in anti-tumor
activity. This component is likely to be TAMs, and
recently Martin-Manso et al. [26] reported that tumor-
produced TSP1 promoted the recruitment of M1-polar-
ized TAMs which stimulated reactive oxygen species
(ROS)-mediated cytotoxicity of the endothelial cells and
thereby caused inhibition of angiogenesis and tumor pro-
gression. By facilitating the infiltration of T AMs with a
M1-phenotype (expressing high levels of iNOS and high
production of NO) over TAMs of the proangiogenic M2-
phenotype, it may be that tasquinimod-induced tumor
levels of TSP1 change the balance between M1 and M2
cells. Thus, changes in such a critical ratio of NO to ROS
generation would be able to destabilize the HIF1α protein
even under hypoxic conditions [45]. This may explain tas-
quinimod's ability to provide an anti-angiogenic milieu by
down-regulate HIF1α protein levels and its down stream
targets, VEGF and Glut-1 proteins in human xenografts
as  t h ey  gr o w  i n  n u d e  m i c e  ( F i g.  5 B  &5 C ) .  I n t e r e s t i n g,
"M2-like" tumor infiltrating myeloid-derived suppressor
cells (MDSCs) is a cell population with a phenotype simi-
lar to M2 macrophages expressing high levels of arginase-
1 [46] and S100A9 protein [47]. The calcium and zink
dependent protein S100A9 regulates the accumulation of
tumor infiltrating MDSCs [48], and tasquinimod as a rep-
resentative of quinoline compounds which recently were
described as a strong binders to S100A9 [44], may have
inhibited the MDSC accumulation and thereby prohib-
ited MDSCs/M2 macrophages to act in a pro-angiogenic
and pro-tumor fashion. Thus, the involvement of an addi-
tional mechanism could be possible, meaning that tas-
quinimod may act in LNCaP tumors both by inducing
TSP1 production and TAM (M1) recruitment and at the
same time inhibit the accumulation of MDSCs and pre-
vent M2 macrophage action via direct interference with
the S100A9 protein in immature myeloid cells. This pos-
sibility will be the subject of future studies of the mecha-
nism of action of tasquinimod.
Conclusions
We conclude that tasquinimod-induced up-regulation of
TSP1 is part of a mechanism involving down-regulation
of HIF1α and VEGF, which in turn leads to reduced
angiogenesis via inhibition of the "angiogenic switch",
that could explain tasquinimod's therapeutic potential
Materials and methods
Cell culture and materials
Tasquinimod was synthesized at Active Biotech Research
AB (Lund, Sweden), as previously described [49]. In this
study tasquinimod was used in vitro at doses between
0.1-100 μM and at 1 and 10 mg/kg/day in vivo, based
upon pharmacokinetic studies [5] where daily oral dosing
with 1-30 mg/kg/day produced serum levels of tasquini-
mod in the 1-4 μM range. Two human prostate cancer
cell lines, CWR-22RH and LNCaP (ATCC) are both
androgen independent, but remain sensitive to androgen
stimulation of growth, express PSA and a mutated andro-
gen receptor [4]. The hormone independent cell lines
LNCaP19 [50] and DU145 were also tested for TSP1
induction after in vitro exposure to tasquinimod. CWR-
22RH, LNCaP and DU145 were grown in RPMI Medium
1640 containing 10% FCS and L-Glutamine mixture,
while LNCAP19 was cultured in RPMI-medium with 10%
hormone free (RDCC) FCS.
Animals
Nude BALB/c mice were used for subcutaneous implan-
tation of human prostate tumor cells LNCaP and CWR-
22RH [4]. All animal experiments were conducted in
accordance with the Bioethics Committee guidelines in
Lund, Sweden. Tumor growth was measured with a
microcaliper twice a week throughout the experiment,
and the final tumor burden was measured by weight on
the day of termination of the experiment. Distribution of
tasquinimod at 1 mg/kg/day and 10 mg/kg/day (adminis-
tered orally via the drinking water) started on day 7 after
inoculation.
RNA preparation
Tissue samples in vitro or  in vivo were collected and
stored at -70°C in Trizol® (Invitrogen). The total RNA was
isolated by extracting the Trizol® samples with chloroform
followed by separation and purification using a modified
protocol for the RNeasy RNA extraction Kit (Qiagen). 1
μl RNAse inhibitor mix was added per 50 μl total RNA
before treatment with DNAse for 20 min (DNA-free™;
Ambion, Austin TX). The RNA concentration and purity
was quality controlled by analysis with a Bioanalyser.
Microarray experiments
LNCaP cells were exposed in vitro to 50 μM tasquinimod
for 24 h before harvest and RNA extraction. Tumor bear-
ing mice (LNCaP inoculated in nude mice) were treated
with tasquinimod at 10 mg/kg (ad.lib.) and the tumors of
each of the 2 different treatment groups were excised
after 24 h of treatment (start day 14 or day 21 after inocu-
lation) and total RNA was isolated. Untreated samples
were grown and harvested in parallel and used as controls
for microarray experiments. The RNA from treated andOlsson et al. Molecular Cancer 2010, 9:107
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control samples were differentially labeled with fluores-
cent dye (Cy3 & Cy5) and hybridized on human oligo-
arrays as described [51]. All hybridizations were repli-
cated using dye-swap for the flourecent dyes, and data
from image-analysis were loaded into a local installation
of BioArray Software Environment (BASE) [52] for pre-
processing and normalization. Spots from dye-swap
hybridization were merged using geometric mean of
ratios requiring presence in both replicates. For spots, log
ratio (M) was calculated as log2(Int1/Int2) (Int1 = treated
sample intensity and Int2 = control intensity) and average
intensity (A) was calculated as log10(Int1*Int2)/2. Nor-
malization was performed by applying Lowess on M val-
ues stratified into 8 separate groups defined spatially by
pin-tip (8 neighboring pin-tips per group). Probe repli-
cates were merged and a probe presence in 3 of 4 biologi-
cal replicates was required for inclusion in further
analysis. All microarray data will be made available in
NCBI's Gene Expression Omnibus (GEO) accessible
through GEO Series entry GSE17031.
Real-time semi-quantitative Reversed Transcriptase-PCR 
(semi-qRT-PCR)
Total RNA was reversed transcribed using the "Tran-
scriptor First Strand cDNA Synthesis Kit" (Roche) and
anchored oligo-(dT)18 primers. PCR primers and fluoro-
genic probes (with an 640 tag) for the human "house-
keeping" gene hGAPDH and the five genes to validate,
THBS1,  CXCR4,  CYP1A1,  GDF15  and  AGER  were
designed, synthesized and purified by TIB MOLBIOL
(Berlin, Germany) (Table 2). Real Time PCR was per-
formed using the "LightCycler FastStart DNAMasterplus
Hybidization Probes" kit (Roche). Cycling parameters
were as follows: Denaturation step for 10 min at 94°C//
Amplification step (40-50 cycles) was 10 s at 95°C _ 10 s
at 56°C _ 20 s at 72°C//30 s at 33°C, the transition rate was
20°C/s for all steps except for 72°C to 90°C which was
10°C/s. To measure up- or down-regulation of cellular
mRNA levels, CP-values (i.e. GAPDH - tested gene) were
calculated from at least three different analysis using var-
ied cDNA concentrations.
Western blotting
SDS-/PAGE and western blot analysis was performed on
the 10,000 g supernatant fraction of total soluble proteins
prepared from cell pellets or from frozen tumor tissue
(100 μg). Briefly, frozen tumor tissue was weighed and
diced into small pieces. Ice cold lysis buffer (20 mM Tris
HCl pH 7.4 with 150 mM NaCl, 1 mM EDTA, 0.5% NP-
40) 0.5% sodium deoxycholate, 1 mM DTT, protease
inhibitor cocktail (Roche), 1.5 mM sodium vanadate, 1
μM cystine and 80 mM sodium glycerophosphate) was
added, homogenized, and centrifuged at 10,000 g for 15
minutes. 10 μg protein was loaded in each lane on a 4-
12% Bis-Tris gel, the protein transferred to a PVDF trans-
fer membrane (Immobilon-P, Millipore), and blocked
overnight in 5% dry fat-free milk in TBST. Incubation
with anti-hTSP1 Ab11 (clones D4.6 + A6.1 + MBC200.1)
or Ab8 (rabbit polyclonal; Lab Vision, NeoMarkers CA,
USA) was performed using mouse anti-human-actin as
an internal control (Sigma). Both antibodies showed
cross-reactivity to mouse derived TSP1 and the detection
patterns were similar for both antibodies (i.e. Ab8 and
Ab11). Recombinant human TSP1 protein (140 kD,
ProSpec-Tany TechnoGene LTD, Israel) was loaded at 3
ng and anti-bodies against androgen receptor (AR; rabbit
polyclonal, (N-20) Santa Cruz), HIF1α (mouse monoclo-
nal from BD) and Glut1 (rabbit polyclonal, (H-43) Santa
Cruz) were all used at 1:500 dilution.
As secondary detection antibodies, (HRP)-conjugated
anti-rabbit antibody or anti-mouse antibodies (Amer-
sham) were used, followed by detection with the
chemoluminiscence ECL-Plus reagent (Amersham, UK),
developed on ECL Hyperfilm (GE Healthcare, UK), cap-
tured and analyzed using a Kodak Digital Science™ Image
Station 440F.
Elisa measurements
VEGF content in tumor tissue and TSP1 levels in cell cul-
ture medium were measured by ELISA (VEGF, Biosurce,
Belgium; #KHG0112, and TSP1, Quantikine® R&D Sys-
tems Europe Ltd, UK; #DTSP10) according to the manu-
facturer's protocol.
Immuno histoflouresence (IHF) microscopy
Tumor tissue, were fixed in 4% paraformaldehyde (PBS),
immersed in 15% and 25% sucrose/PBS, tissues were
mounted in Tissue-Tek (Sakura Finetek Europe, Nether-
land) and immediately frozen on carbon dioxide ice. Cry-
osections were cut (10 μm) and two sections were
collected per slide, comprising at least two levels of the
tumor. General tissue morphology was visualized by
hematoxylin and eosin staining. For immunohisto-fluo-
rescence (IHF) labeling of frozen tissue sections was the
anti-human TSP1 antibody (Ab8).IHF labeling was
accompanied by nuclear staining with DAPI (Molecular
Probes, USA).
Statistical analysis
For microarray experiments, genes were selected for up-
or down-regulated transcript expression after exposure
to tasquinimod compared to non-exposed controls.
Using independent biological replicates the probability of
observed mean M was calculated for each reporter using
a BASE plug-in implementation of one-class Z-test [52]
with the null hypothesis that the reporter is non-differen-
tially expressed. The null distribution was derived from
pooled standard deviation and mean for the biologicalOlsson et al. Molecular Cancer 2010, 9:107
http://www.molecular-cancer.com/content/9/1/107
Page 12 of 14
Table 2: Primer and probe sets used for RT-PCR and semi-quantitative real time PCR*.
Target gene Primer
Sequence (5' => 3')
Probe†
Sequence (5' => 3')
Amplicon 
length (bp)
hu GAPDH FW: gAAggTgAAggTCggAgTC
Rev: gAAgATggTgATgggATTTC
AggggTCATTgATggCAACAATATCCA-FL
LC:640-TTTACCAgAgTTAAAAgCAgCCCTggTg
226
hu TSP-1 FW: CTggACTCgCTgTAggTTA
Rev: CCCTgTggTggAgTTTAC
AgTCATCgTCCCTTTCggTg-FL
LC: 640-TgATgAAgAAggTgCCACTgAAgT
233
hu CXCR4 FW: CgAggAAATgggCTCAg
Rev: gggAAgCgTgATgACAAA
TTTTATTgAAATTAgCATTTTCTTCACggA-FL
LC:640-ACAgggTTCCTTCATggAgTCATAgTCC
273
hu CYP1A1 FW: gAgCTgggTTTgACACAgTC
Rev: ggATgTAAAAgCCTTTCAAACT
gTCggAAggTCTCCAggATgAAg-FL
LC: 640-CCTCCATATAgggCAgATgggATCTg
258
hu GDF15 FW:gAAgACTCCAgATTCCgAgAgTT
Rev:gATCCCAgCCgCACTTCT
gATTCgAACACCgACCTCgTCCC-FL
LC: 640-gCCCCTgCAgTCCggATACTCAC
146
hu AGER FW: TCTgCCTCTgAACTCACgg
Rev: CCTTCACAgATACTCCCTTCTCATT
CAgggACTCTTAgCTggCACTTgg--FL
LC: 640-TgggAAAgCCCCTggTgCCT
139
huTSP-1‡ FW: AACggAgTTCAgTACAgAAAT
Rev: TTCCATTgCCACAgCTC
CAgAACTCRgTTACCATCTgCAAAAAgg-FL
LC: 640-gTCCTgYCCCATCATgCCCTgC
235
mTsp-1‡ FW: AgAgAACAgAgAgCTggTCAg
Rev: ATCTgTTgTTgAggCTgTCA
329
mPbgd FW:TTgTACCCTggCATACAgTTTgA
Rev: gTTCCCACggCACTTTTC
TgAAggATgTgCCTACCATACTACCTCCT-FL
LC: 640-gCTTTACTATTggAgCCATCTgCAAAC
247
* Designed, synthesized and purified by TIB MOLBIOL (Berlin, Germany)
† Probes designated LC contain the acceptor dye LigtCycler Red 640 covalently attached at the 5'-end, and the FL probes contain the donor 
dye Fluorescein at the 3'-end.
‡ Specific mouse- and human TSP1 primers sharing the same LC/FL probe sequence for TSP1.
replicates. Obtained probabilities (P) were used to rank
reporters and to calculate expected number of reporters
(expected) for each rank. False discovery rate (FDR) was
estimated by comparing the expected number of report-
ers and rank, i.e., expected/rank. To select differentially
expressed reporters a cut-off was set at false discovery
rate 10% (FDR < 0.10) [52].
The statistical significance of difference between exper-
imental conditions was determined using One-way
ANOVA analysis (p ≤ 0.05 based on F values) with two-
tailed Student's t-test with Bonferroni's correction for
comparison of multiple groups, (*) p ≤ 0.05 and (**) p ≤
0.01.
Additional material
Additional file 1 Table S1 - Genes up- and down regulated at FDR < 
0.1 (10%) after in vitro exposure to Tasquinimod for 24 h. The indicated 
column headings (bold) are explained as follows (also indicated as foot 
notes): (+) indicates up-regulation in treated vs untreated and (-) indicates 
down-regulation in treated versus untreated*, Absolute fold change 
between untreated and treated cells†, Average M of biological replicates‡, 
n = number of biological replicates**, P = probability of obtaining the 
observed average M (Z-test) ††, Rank = ranked genes based on obtained 
probabilities (i.e., the reporter with lowest P will have rank 1) ‡‡, Expected 
= expected number of reporters calculated as probability times total num-
ber of reporters ***, and FDR = number of expected number of reporters 
divided by observed number of reporters (rank) ‡‡‡.Olsson et al. Molecular Cancer 2010, 9:107
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